IBD: Diagnosis and Evaluation

  • Walter A. Koltun


In 1932, Crohn, Ginzburg, and Oppenheimer described 13 patients with “regional ileitis” included in a total of 52 cases of nonspecific granulomatous inflammation of the intestine.1 Prior to their publication, numerous others had reported various cases of what were in retrospect, probably Crohn’s disease (CD), as early as 1813,2 but it was their published description that established the formal classification of the disease syndrome and association with noncaseating granulomas. The surgeon involved in the care of the majority of the patients, Dr. AA Berg, did not want his name included in the article. Because of the variable clinical and anatomic manifestations of the illness, “CD” has subsequently become as common a descriptor of this disease entity as the term “regional enteritis.”


  1. 1.
    Crohn BB, Ginzburg L, Oppenheimer GD. Regional Ileitis. AMA Am J Dis Child. 1932;99:1323–9.Google Scholar
  2. 2.
    Combe C, Saunders W. A singular case of stricture and thickening of the ileum. Med Trans Royal Soc Med 1806;16–18.Google Scholar
  3. 3.
    Brooke BN. Granulomatous disease of the intestine. Lancet 1959;2(7106):745–9.Google Scholar
  4. 4.
    Lockhart-Mummery HE, Morson BC. Crohn’s disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut. 1960;1:87–105.CrossRefGoogle Scholar
  5. 5.
    Brooke BN. The management of an ileostomy including its complications. Dis Colon Rectum. 1993;36:512–6.CrossRefGoogle Scholar
  6. 6.
    Truelove SC, Witts LJ, Bourne WA, et al. Cortisone and corticotropin in ulcerative colitis. Br Med J. 1959;1(5119):387–94.Google Scholar
  7. 7.
    Gitnick G. Inflammatory bowel disease: diagnosis and treatment. New York: Igaku-Shoin; 1991.Google Scholar
  8. 8.
    Korelitz BI. Immunosuppressive therapy of inflammatory bowel disease: a historical perspective. Gastroenterologist. 1995;3(2):141–52.PubMedGoogle Scholar
  9. 9.
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necros factor alpha for Crohn’s disease. Crohn’s disease cA2 study group. N Engl J Med. 1997;337(15):1029–35.CrossRefGoogle Scholar
  10. 10.
    Dennis C. Ileostomy and colectomy in chronic ulcerative colitis. Surgery. 1945;18:435–52.Google Scholar
  11. 11.
    Strauss AA, Strauss SF. Surgical treatment of ulcerative colitis. Surg Clin North Am. 1944;24:211–24.Google Scholar
  12. 12.
    Koch NG. Intra-abdominal reservoir in patients with permanent ileostomy. Arch Surg. 1969;99:223–31.CrossRefGoogle Scholar
  13. 13.
    Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. Br Med J. 1978;2:85–8.CrossRefGoogle Scholar
  14. 14.
    Utsunomiya J. Restorative proctocolectomy for ileal reservoir. Int J Colorectal Dis. 1986;1:2–19.CrossRefGoogle Scholar
  15. 15.
    Ekbom A, Helmick C, Zack M, et al. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology. 1991;100:350–8.CrossRefGoogle Scholar
  16. 16.
    Yang SK, Hong WS, Min YI, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong district, Seoul, Korea. J Gastroenterol Hepatol. 2000;15:1037–42.CrossRefGoogle Scholar
  17. 17.
    Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology. 1991;100:143–9.CrossRefGoogle Scholar
  18. 18.
    Loftus Jr EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systemic review. Aliment Pharmacol Ther. 2002;16:51–60.CrossRefGoogle Scholar
  19. 19.
    Blanchard JF, Bernstein CN, Wajda A, et al. Small-area variations and sociodemographic correlates for the incidence of Crohn’s disease and ulcerative colitis. Am J Epidemiol. 2001;154:328–35.CrossRefGoogle Scholar
  20. 20.
    Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn’s disease in the country of Copenhagen 1962-87: a sixfold increase in incidence. Scand J Gastroenterol. 1992;27:609–14.CrossRefGoogle Scholar
  21. 21.
    Gilat T, Grossman A, Fireman Z, et al. Inflammatory bowel disease in Jews. Front Gastrointest Res. 1986;11:135–40.CrossRefGoogle Scholar
  22. 22.
    Sonnenberg A. Occupational distribution of inflammatory bowel disease among German employees. Gut. 1990;31:1037–40.CrossRefGoogle Scholar
  23. 23.
    Reif S, Klein I, Lubin F, et al. Pre-illness dietary factors in inflammatory bowel disease. Gut. 1997;40:754–60.CrossRefGoogle Scholar
  24. 24.
    Boyko EJ, Perera DR, Koepsell TD, et al. Coffee and alcohol use and the risk of ulcerative colitis. Am J Gastroenterol. 1989;84:530–4.PubMedGoogle Scholar
  25. 25.
    Tanner AR, Raghunath AS. Colonic inflammation and nonsteroidal anti-inflammatory drug administration. An assessment of the frequency of the problem. Digestion. 1988;41:116–20.CrossRefGoogle Scholar
  26. 26.
    Vessey M, Jewell D, Smith A, et al. Chronic inflammatory bowel disease, cigarette smoking, and use of oral contraceptives: findings in a large cohort study of women of childbearing age. Br Med J (Clin Res Ed). 1986;292:1101–3.CrossRefGoogle Scholar
  27. 27.
    Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;34:1841–54.CrossRefGoogle Scholar
  28. 28.
    Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40(8):955–62.CrossRefGoogle Scholar
  29. 29.
    Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461–3.CrossRefGoogle Scholar
  30. 30.
    Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009;41(2):216–20.CrossRefGoogle Scholar
  31. 31.
    Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn’s disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39(5):596–604.CrossRefGoogle Scholar
  32. 32.
    The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–78.CrossRefGoogle Scholar
  33. 33.
    Lees CW, Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev Gastroenterol Hepatol. 2009;3(5):513–34.CrossRefGoogle Scholar
  34. 34.
    Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603–6.CrossRefGoogle Scholar
  35. 35.
    Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNP’s identifies a susceptibility variant for Crohn’s disease in ATG16L1. Nat Genet. 2007;39(2):207–11.CrossRefGoogle Scholar
  36. 36.
    Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8(6):458–66.CrossRefGoogle Scholar
  37. 37.
    Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361(21):2033–45.CrossRefGoogle Scholar
  38. 38.
    Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the working party for the world congresses of gastroenterology Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.CrossRefGoogle Scholar
  39. 39.
    Louis E, Collard A, Oger AF, et al. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–82.CrossRefGoogle Scholar
  40. 40.
    Bernstein CN, Blanchard JF, Rawsthorne P, et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116–22.CrossRefGoogle Scholar
  41. 41.
    Generini S, Giacomelli R, Fedi R, et al. Infliximab in spondyloarthropathy associated with Crohn’s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63(12):1664–9.CrossRefGoogle Scholar
  42. 42.
    Nahar IK, Shojania K, Marra CA, et al. Infliximab treatment of rheumatoid arthritis and Crohn’s disease. Ann Pharmacother. 2003;37(9):1256–65.CrossRefGoogle Scholar
  43. 43.
    Sheldon DG, Sawchuk LL, Kozarek RA, et al. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg. 2000;135(5):564–8.CrossRefGoogle Scholar
  44. 44.
    Powell FC, Schroeter AL, Su WPD, et al. Pyoderma gangrenosum: a review of 86 patients. Q J Med. 1985;217:173–86.Google Scholar
  45. 45.
    Poritz LS, Koltun WA. Surgical management of ulcerative colitis in the presence of primary sclerosing cholangitis. Dis Colon Rectum. 2003;46(2):173–8.CrossRefGoogle Scholar
  46. 46.
    Cohen S. Liver disease and gallstones in regional enteritis. Gastroenterology. 1971;60:237–45.PubMedGoogle Scholar
  47. 47.
    Talbot RW, Heppel J, Dozois RR, et al. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140–5.CrossRefGoogle Scholar
  48. 48.
    Fichera A, Cicchiello LA, Mendelson DS, et al. Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain. Dis Colon Rectum. 2003;46(5):643–8.CrossRefGoogle Scholar
  49. 49.
    Remzi RH, Fazio VW, Oncel M, et al. Portal vein thrombi after restorative proctocolectomy. Surgery. 2002;132(4):655–61.CrossRefGoogle Scholar
  50. 50.
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index, national cooperative Crohn’s disease study. Gastroenterology. 1976;70:439–44.PubMedGoogle Scholar
  51. 51.
    Poritz LS, Koltun WA. Techniques of disease activity assessment in Crohn’s disease. Semin Colon Rectal Surg. 2001;12(1):16–21.Google Scholar
  52. 52.
    Pikarsky AJ, Gervaz P, Wexner SD. Perianal Crohn’s disease: a new scoring system to evaluate and predict outcome of surgical intervention. Arch Surg. 2002;137:774–7.CrossRefGoogle Scholar
  53. 53.
    Powell-Tuck J, Day DW, Buckell NA, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci. 1982;27:533–7.CrossRefGoogle Scholar
  54. 54.
    Rutegard I, Ahsgren L, Stenling R, et al. A simple index for assessment of disease activity in patients with ulcerative colitis. Hepatogastroenterology. 1990;37:110–2.PubMedGoogle Scholar
  55. 55.
    Carucci LR, Levine MS. Radiographic imaging of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31(1):93–117.CrossRefGoogle Scholar
  56. 56.
    Maccioni F, Viscido A, Broglia L, et al. Evaluation of Crohn’s disease activity with magnetic resonance imaging. Abdom Imaging. 2000;25:219–28.CrossRefGoogle Scholar
  57. 57.
    Schreyer AG, Golder S, Seitz J, et al. New diagnostic avenues in inflammatory bowel diseases. Capsule endoscopy, magnetic resonance imaging and virtual enteroscopy. Dig Dis. 2003;21(2):129–37.CrossRefGoogle Scholar
  58. 58.
    Borley NR, Mortensen NJ, Jewell DP. MRI scanning in perianal Crohn’s disease: an important diagnostic adjunct. Inflamm Bowel Dis. 1999;5(3):231–3.CrossRefGoogle Scholar
  59. 59.
    Koelbel G, Schmiedl U, Majer MC, et al. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. AJR Am J Roentgenol. 1989;152:999–1003.CrossRefGoogle Scholar
  60. 60.
    O’Donovan AN, Somers S, Farrow R, et al. MR imaging of anorectal Crohn disease: a pictorial essay. Radiographics. 1997;17(1):101–7.CrossRefGoogle Scholar
  61. 61.
    Bell SJ, Halligan S, Windsor AC, et al. Response of fistulating Crohn’s disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2003;17(3):387–93.CrossRefGoogle Scholar
  62. 62.
    Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol. 2003;98(2):332–9.CrossRefGoogle Scholar
  63. 63.
    Gasche C, Moser G, Turetschek K, et al. Transabdominal bowel sonography for detection of intestinal complication in Crohn’s disease. Gut. 1999;44:112–7.CrossRefGoogle Scholar
  64. 64.
    Arndt JW, Grootscholten MI, van Hogezand RA, et al. Inflammatory bowel disease activity assessment using technetium-99m-HMPAO leukocytes. Dig Dis Sci. 1997;42:387–93.CrossRefGoogle Scholar
  65. 65.
    Gevers AM, Couckuyt H, Coremans G, et al. Efficacy and safety of hydrostatic balloon dilation of ileocolonic Crohn’s strictures: a prospective long-term analysis. Acta Gastroenterol Belg. 1994;57:320–2.PubMedGoogle Scholar
  66. 66.
    Iddan G, Meron G, Glukhovsky A, et al. Wireless capsule endoscopy. Nature. 2000;405:417.CrossRefGoogle Scholar
  67. 67.
    Fireman Z, Mahajna E, Broide E, et al. Diagnosing small bowel Crohn’s disease with wireless capsule endoscopy. Gut. 2003;52:390–2.CrossRefGoogle Scholar
  68. 68.
    Guindi M, Riddell RH. Indeterminate colitis. J Clin Pathol. 2004;57:1233–44.CrossRefGoogle Scholar
  69. 69.
    Camilleri M, Proano M. Advances in the assessment of diseases activity in inflammatory bowel disease. Mayo Clin Proc. 1989;64:800–7.CrossRefGoogle Scholar
  70. 70.
    Brignola D, Lanfarnchi GA, Campieri M, et al. Importance of laboratory parameters in the evaluation of Crohn’s disease activity. J Clin Gastroenterol. 1986;8:245–8.CrossRefGoogle Scholar
  71. 71.
    Louis E, Belaich J, Kemseke CV, et al. Soluble interleukin-2 receptor in Crohn’s disease: assessment of disease activity and prediction of relapse. Dig Dis Sci. 1995;40:1750–6.CrossRefGoogle Scholar
  72. 72.
    Cambridge G, Rampton DS, Stevens TR, et al. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1992;33:668–74.CrossRefGoogle Scholar
  73. 73.
    Sandborn WJ, Landers CJ, Tremain WJ, et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Clin Proc. 1996;71:431–6.CrossRefGoogle Scholar
  74. 74.
    Sanborn WJ, Landers CJ, Tremain WJ, et al. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch anal anastomosis. Am J Gastroenterol. 1995;90:740–7.Google Scholar
  75. 75.
    Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:559–603.CrossRefGoogle Scholar
  76. 76.
    Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn’s disease. Gastroenterology. 2002;122:854–66.CrossRefGoogle Scholar
  77. 77.
    Lesage S, Zouali H, Cezard JP, et al. CARD 15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845–57.CrossRefGoogle Scholar

Copyright information

© ASCRS (American Society of Colon and Rectal Surgeons) 2011

Authors and Affiliations

  • Walter A. Koltun
    • 1
  1. 1.Division of Colon and Rectal Surgery, Department of SurgeryPenn State Milton S. Hershey Medical CenterHersheyUSA

Personalised recommendations